Immutep IMMP
NASDAQ IMMP
$0.36 -0.01 (-2.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Immutep (IMMP) Non-Current Assets (2011 - 2026)

Immutep's (IMMP) quarterly Non-Current Assets came in at $1.9 million in Q2 2026, down 62.9% on a YoY basis from $5.1 million in Q2 2025, and down 61.51% quarter-over-quarter from $4.9 million in Q4 2025.

Analysis

Immutep (IMMP) Non-Current Assets (2011 - 2026) Analysis & Trends

Immutep (IMMP) has reported Non-Current Assets for 16 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non-Current Assets fell 62.9% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 million (down 62.9% YoY), and the FY2026 full-year result was $1.9 million, down 62.9% from the prior year.
  • Non-Current Assets retreated to $1.9 million in Q2 2026 per IMMP's latest filing, from $4.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $8.3 million in Q2 2023 and bottomed at $1.9 million in Q2 2026.
  • Historically, Non-Current Assets has averaged $6.1 million across 5 years, with a median of $6.7 million in 2024.
  • The sharpest annual moves came in 2023 and 2026: Non-Current Assets climbed 2.56% in 2023, then sank 62.9% in 2026.
  • Over 5 years, Non-Current Assets stood at $7.1 million in 2022, then dropped by 1.29% to $7.0 million in 2023, then dropped by 19.98% to $5.6 million in 2024, then decreased by 13.08% to $4.9 million in 2025, then plunged by 61.51% to $1.9 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $1.9 million, $4.9 million, and $5.1 million for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 1.96 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 564.41 Mn
10 Immutep 51.68 Mn 51.68 Mn - 1.87 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.87 Mn
Dec 31, 2025 4.87 Mn
Jun 30, 2025 5.05 Mn
Dec 31, 2024 5.60 Mn
Jun 30, 2024 6.74 Mn
Dec 31, 2023 7.00 Mn
Jun 30, 2023 8.34 Mn
Dec 31, 2022 7.09 Mn
Jun 30, 2022 8.14 Mn
Dec 31, 2021 9.15 Mn
Jun 30, 2021 10.48 Mn
Dec 31, 2020 10.38 Mn
Jun 30, 2020 10.12 Mn
Dec 31, 2019 11.00 Mn
Jun 30, 2019 11.91 Mn
Jun 30, 2018 13.90 Mn
Dec 31, 2017 14.40 Mn
Jun 30, 2017 14.31 Mn
Mar 31, 2017 13.87 Mn
Dec 31, 2016 19.50 Mn